rugada syndrome is a cardiac sudden-death syndrome in healthy adults that is electrocardiographically characterized by a coved-type ST-segment elevation in the right precordial leads of the electrocardiography (ECG). This strange ST-segment elevation is usually called the 'Brugada sign' and it indicates the diagnosis of Brugada syndrome (BS), which is considered to be a predictor of ventricular fibrillation. 1 A saddleback-type ST-segment elevation is often detected in the right precordial leads in the clinical situation, but it is unknown whether it is related to BS. Recently, ECG recorded from a higher intercostal space (HICS ECG), after the administration of procainamide, has been reported as useful for the detection of the Brugada sign in survivors of sudden unexplained death syndrome and their relatives. 2 In this study, the clinical significance of HICS ECG in cases with the Brugada sign and the saddleback-type was investigated.
Case with the Brugada sign (52-year-old, male). The Brugada sign was detected in both the V1 and V2 leads of the standard 12-lead ECG, compared with the V1, V2, and V3 leads on the HICS ECG. HICS, higher intercostal space. Case with the Brugada sign (67-year-old, male). The Brugada sign was detected in the V1 lead only of the standard 12-lead ECG, whereas in the HICS ECG, the area in which the sign was detectable spread to include both the V1 and V2 leads. HICS, higher intercostal space.
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lead ECG in 28 cases (9 symptomatic BS group, 19 asymptomatic BS group); however, in the HICS ECG, the Brugada sign was exhibited in the V1 lead only in 13 cases, and in the remaining 15 cases, the area in which the sign was detectable spread to include both the V1 and V2 leads (Fig 2) . On the 12-lead ECG the Brugada sign was detected in both the V1 and V2 leads in 8 cases (4 symptomatic BS group, 4 asymptomatic BS group) and in 6 cases on the HICS ECG and in the remaining 2 cases, it was detected in the V1, V2, and V3 leads (Fig 3) . In 1 case the Brugada sign was detected in the V1-3 leads of both the 12-lead ECG and the HICS ECG (Fig 4) .
Of the 76 cases with the asymptomatic saddleback-type, the Brugada sign was unmasked by the HICS ECG in only 1 case in which a 0.1 mV elevation was detected in the V1 lead and 0.2 mV elevation in the V2 lead (Fig 5) .
Of the 113 cases, the Brugada sign was detected in 47 leads using the 12-lead ECG compared with 66 leads in the HICS ECG; however, in the asymptomatic saddleback group, the Brugada sign was rarely detected.
Amplitude of the J-Point and ST-Segment
A comparison of the amplitudes of the J-point and the ST-segment measured from the 12-lead ECG and the HICS ECG is shown in Fig 6. At the J-point, no significant difference was observed in any of the subjects, but when they were divided into the different groups, the amplitude of the J-point in the asymptomatic saddleback-type group decreased in leads V1 and V2 (p<0.01, respectively) and increased in leads V2 and V3 in the asymptomatic BS group (p<0.05, respectively). In the symptomatic BS group, the amplitude of the J-point increased in the V1 lead only (p<0.05).
In comparison with the 12-lead ECG, a significant decrease (p<0.01) was observed in the amplitude of the ST-segment on the HICS ECG. When the subjects were divided into the symptomatic BS, asymptomatic BS, and asymptomatic saddleback groups, a significant decrease (p<0.01, respectively) was also observed on the HICS ECG.
From these measurements, the following characteristics of the HICS ECG were identified: (1) a decrease in the amplitude of the J-point in the asymptomatic saddleback group; (2) an increase in the amplitude of the J-point in the symptomatic (only in V1) and asymptomatic (in V2 and V3) BS groups; and (3) a decrease in the amplitude of the STsegment in all groups (in V1-V3).
Discussion
BS was originally described by Brugada P and Brugada J in 1992 3 and it appears that this syndrome originates from abnormal electrophysiological activity resulting from a genomic cardiac channelopathy. The prognosis of BS is poor, and at present an implantable cardioverter defibrillator is the only recommended treatment. Although there are many asymptomatic individuals, their management remains controversial. As a predictor for ventricular fibrillation (VF) susceptibility, Brugada et al 1 supported the inducibility of VF in an electrophysiological study, but as that examination does not easily identify all asymptomatic individuals, there is a need for a noninvasive method of predicting VF. Some noninvasive examinations have been proposed, but they have failed to show sufficient significance in distinguishing those with a high risk for BS. We have reported the significance of the dispersion of the activation recovery time, 4 and that of ventricular late potentials 5 and the association between RR interval and QT-interval 6 have also been discussed. However, none of these examinations was sufficient for the prediction of VF susceptibility. At present, VF susceptibility is not consistently predicted by noninvasive examinations. If the patient agrees to an electrophysiological study, and VF inducibility is confirmed, an implantable cardioverter defibrillator is implanted.
Furthermore, problems with the diagnosis are not rare and because the Brugada sign can be missed 1 (eg, when the ECG may show the saddleback-type ST-segment elevation and then return to normal), a method with higher probability is needed. Although the saddleback-type ST-segment elevation may sometimes be detected in a medical checkup, it is difficult to decide whether or not those cases could exhibit the Brugada sign in other situations. The Na channel blockers are widely used to unmask the Brugada sign, 7, 8 but there is skepticism about whether the drug tolerance test can identify those individuals who have shown the asymptomatic saddleback-type during a medical check-up. Shimizu et al reported that body surface mapping studies using ECG recordings from the second and third intercostal spaces help detect the Brugada sign in patients with BS and in those with the Brugada sign unmasked by Na channel blockade. 9 Most recently, Sangwatanaroj et al reported that ECG recordings from one intercostal space higher than usual was helpful in detecting the Brugada sign induced by procainamide administration in patients who had survived unexpected death syndrome in Thailand. 2 We consider that it is easy to change the ECG recording site for an ECG during a medical check-up.
Our results showed that in patients with the Brugada sign observed on the 12-lead ECG, the sign can also be detected on the HICS ECG and furthermore, the area in which the Brugada sign is detectable is greater than when using the 12-lead ECG,; there was only 1 individual with the saddleback-type ST-segment elevation in whom the Brugada sign was unmasked by the HICS ECG.
The area in which the Brugada sign could be detected became greater when recording from a higher intercostal space than when using the 12-lead ECG in patients in whom the Brugada sign was observable in the 12-lead ECG. In the cases in which the Brugada sign was detected, the amplitude of the J-point increased and that of the STsegment decreased on the HICS ECG, most likely resulting in the coved-type ST-segment elevation. However, in the asymptomatic saddleback group, both the amplitude of the J-point and ST-segment tended to decrease on the HICS ECG. Therefore, if the Brugada sign is not detected in the 12-lead ECG in individuals with an increased amplitude of the J-point, recording a HICS ECG may be helpful to detect the Brugada sign.
In the cases in which the Brugada sign was detectable on the 12-lead ECG, the sign was always detectable on the HICS ECG and furthermore, the area in which the Brugada sign was detectable was greater than when using the 12-lead ECG. Because the HICS ECG is easy to use, it should always be performed and should be recorded first. 
Conclusion
The ability of the HICS ECG to detect the Brugada sign was investigated. The area in which the sign was detectable was greater when recording from a higher intercostal space than when using the 12-lead ECG. In cases with the Brugada sign, the amplitude of the J-point was increased and the amplitude of the ST-segment was decreased, therefore the Brugada sign was accentuated. We consider that HICS ECG is helpful for the detection of the Brugada sign.
